Welcome to our dedicated page for Tenon Medical SEC filings (Ticker: TNON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tenon Medical, Inc. filings document its medical-device business, public securities, and material events tied to sacroiliac joint treatment products. Current Reports on Form 8-K cover financial results, unaudited revenue releases, FDA-cleared product updates, and corporate communications related to the Catamaran System and SImmetry® portfolio.
The filing record also discloses securities purchase agreements, senior convertible notes, private placements of common stock and warrants, restricted stock unit grants under the 2022 Equity Incentive Plan, annual meeting voting matters, Nasdaq listing-compliance notices, and amended acquisition disclosures with financial statements and pro forma information for the SiVantage asset acquisition.
Tenon Medical, Inc. filed a Form S-8 to register 1,208,882 shares of common stock for issuance under its 2022 Equity Incentive Plan, as amended. These shares include 70,387 shares already reserved but not previously registered and 1,138,495 shares added under a September 2025 stockholder-approved amendment. The plan’s share figures are presented on a post-split basis, reflecting the company’s 1-for-10 reverse stock split in November 2023 and 1-for-8 reverse stock split in September 2024. The filing updates prior S-8 registrations and incorporates the company’s recent annual, quarterly, and current reports by reference.
Tenon Medical, Inc. filed an 8-K dated September 23, 2025 that lists its publicly traded securities and records signatures and share-count figures for several named officers and directors. The document references Common Stock (par value $0.001) trading under the symbol TNON and Warrants trading under TNONW on The Nasdaq Stock Market. Individual entries show numeric holdings for Steven Foster, Richard Ginn, Stephen Hochschuler, MD, Ivan Howard, Kristine Jacques, and Robert Weigle, and the filing is executed by Steven M. Foster in his capacity as Chief Executive Officer and President.
Tenon Medical, Inc. has rescheduled its previously adjourned Annual Meeting to be held virtually on September 18, 2025, at 10:30 a.m. Pacific Time. The meeting had been adjourned on July 23, 2025 and August 20, 2025.
Only shareholders of record at the close of business on August 22, 2025 are entitled to notice and to vote. Stockholders must use a Virtual Control Number to participate and vote electronically, with additional steps required for those holding shares in “street name.” The company urges shareholders to vote before September 16, 2025 to ensure their votes are received and counted.
Nathaniel A. Grawey, Chief Commercial Officer of Tenon Medical (TNON), reported beneficial ownership on a Form 3. He directly holds 138,114 shares of common stock, which are stated to be subject to a vesting schedule and non-transferable, and has an indirect interest in 175,383 shares through SiVantage, Inc. SiVantage owns 710,300 shares and Grawey holds 24.69% of that company.
Tenon Medical, Inc. reported quarterly revenue of $564,000 and six‑month revenue of $1.29 million, down from $901,000 and $1.62 million a year earlier, driven by fewer procedures using The Catamaran System. Gross profit fell and margins compressed, while the company recorded a net loss of $2.769 million for the quarter and $6.385 million for the six months, contributing to an accumulated deficit of $75.1 million. Cash and cash equivalents totaled $7.846 million at June 30, 2025, bolstered by $6.2 million of net financing in the first half of 2025.
Management discloses substantial doubt about the company’s ability to continue as a going concern for the next 12 months and plans to seek additional capital. Subsequent events include the acquisitions of SImmetry (closed Aug 1, 2025) and SIMPL (closed Aug 4, 2025), which transfer IP and product assets for cash, shares and royalty arrangements; the transactions also include executive hires with equity compensation. The company reported a material weakness in internal controls related to segregation of duties.
Tenon Medical's Chief Innovation Officer, Wyatt D. Geist, filed a Form 3 reporting beneficial ownership related to an 08/01/2025 event. He directly holds 138,114 common shares (noted as subject to a vesting schedule and non-transferable) and has an indirect interest of 350,765 shares through SiVantage, Inc. SiVantage owns 710,300 shares and Geist holds a 49.38% equity interest in that company.
Tenon Medical acquired substantially all assets and intellectual property of SiVantage's SImmetry business and of SIMPL, including technologies for sacropelvic fixation and posterior sacroiliac implants. Consideration to SiVantage included $750,000 cash, 710,300 shares of common stock (with 473,533 shares held by Tenon for one year as indemnity security), tiered royalties and contingent payments, and potential earnout equity. Royalties for SImmetry start at 15% then drop to 10% (capped at $5.0 million); SIMPL royalties begin at 30% (reducing to 20% after aggregate payments exceed $20.0 million). SiVantage and two related executives together beneficially own 986,528 shares, about 12.5% of outstanding stock, and two SiVantage principals were appointed to Tenon management and received 138,114 shares each.